EP1689408A4 - Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines - Google Patents

Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines

Info

Publication number
EP1689408A4
EP1689408A4 EP04812836A EP04812836A EP1689408A4 EP 1689408 A4 EP1689408 A4 EP 1689408A4 EP 04812836 A EP04812836 A EP 04812836A EP 04812836 A EP04812836 A EP 04812836A EP 1689408 A4 EP1689408 A4 EP 1689408A4
Authority
EP
European Patent Office
Prior art keywords
benzodiazepines
epithelium
treatment
low dose
inflammatory disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04812836A
Other languages
German (de)
French (fr)
Other versions
EP1689408A1 (en
Inventor
Steven M Leventer
Robert F Kucharik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vela Acquisition Corp
Original Assignee
Vela Acquisition Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/038643 external-priority patent/WO2004050080A1/en
Application filed by Vela Acquisition Corp filed Critical Vela Acquisition Corp
Publication of EP1689408A1 publication Critical patent/EP1689408A1/en
Publication of EP1689408A4 publication Critical patent/EP1689408A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP04812836A 2003-12-03 2004-12-03 Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines Withdrawn EP1689408A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2003/038643 WO2004050080A1 (en) 2002-12-03 2003-12-03 Treatment of inflammatory disorders with 2,3-benzodiazepines
US10/727,940 US20040138209A1 (en) 2002-12-03 2003-12-03 Treatment of inflammatory disorders with 2,3- benzodiazepines
PCT/US2004/040403 WO2005056017A1 (en) 2003-12-03 2004-12-03 Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines

Publications (2)

Publication Number Publication Date
EP1689408A1 EP1689408A1 (en) 2006-08-16
EP1689408A4 true EP1689408A4 (en) 2010-03-03

Family

ID=34680839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04812836A Withdrawn EP1689408A4 (en) 2003-12-03 2004-12-03 Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines

Country Status (4)

Country Link
EP (1) EP1689408A4 (en)
JP (1) JP2007513171A (en)
CA (1) CA2548038A1 (en)
WO (1) WO2005056017A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050080A1 (en) * 2002-12-03 2004-06-17 Vela Pharmaceuticals, Inc. Treatment of inflammatory disorders with 2,3-benzodiazepines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1124556T3 (en) * 1998-10-27 2004-10-11 Vela Pharmaceuticals Inc Use of optically pure (R) -tophisopam for the treatment and prevention of anxiety disorders
US6080736A (en) * 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
FR2824065A1 (en) * 2001-04-26 2002-10-31 Neuro3D COMPOUNDS INHIBITORS OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, PREPARATION AND USES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050080A1 (en) * 2002-12-03 2004-06-17 Vela Pharmaceuticals, Inc. Treatment of inflammatory disorders with 2,3-benzodiazepines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KONO T ET AL: "CLINICAL EVALUATION OF TOFISOPAM GRANDAXIN ON SEVERAL DERMATOLOGICAL DISEASES IN PATIENTS WITH PSYCHOSOMATIC SYMPTOMS", HIFU, vol. 33, no. 6, 1991, pages 699 - 707, XP009128521, ISSN: 0018-1390 *
LEVENTER STEVEN M ET AL: "The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 99, no. 10, Suppl. S, October 2004 (2004-10-01), & 69TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; ORLANDO, FL, USA; OCTOBER 29 -NOVEMBER 03, 2004, pages S279, XP009128474, ISSN: 0002-9270 *
See also references of WO2005056017A1 *
YOSHIKAWA K ET AL: "Clinical evaluation of Grandaxin(R) (tofisopam) on several skin diseases", SKIN RESEARCH 1993 JP, vol. 35, no. 1, 1993, pages 195 - 202, XP009128520, ISSN: 0018-1390 *

Also Published As

Publication number Publication date
WO2005056017A1 (en) 2005-06-23
JP2007513171A (en) 2007-05-24
CA2548038A1 (en) 2005-06-23
EP1689408A1 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
EP1490044A4 (en) Combination therapy for the treatment of conditions with pathogenic inflammatory components
ZA200401004B (en) Combination for the treatment of inflammatory disorders
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
MXPA03002814A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
EP1622589A4 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
AP1997A (en) 3-(3,5-dioxo-4,5-dihydro-3H-(1,2,4)triazin-2-YL)-benzamide derivatives as P2X7-inhibitors for the treatment of inflammatory diseases
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
PT1656346E (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
EP1638508A4 (en) Shunt for the treatment of glaucoma
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
MXPA03002813A (en) Compounds useful in the treatment of inflammatory diseases.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
IL173351A0 (en) Therapy of ocular disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
EP1581206A4 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
ZA200505989B (en) Use the steroids to treat ocular disorders
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EP1689408A4 (en) Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
EP1697536A4 (en) Novel oligonucleotides and treating cardiac disorders by using the same
HRP20041159A2 (en) Combination for the treatment of airway disorders
WO2009024325A3 (en) Treatment of sleep disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VELA ACQUISITION CORPORATION

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100203

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/551 20060101ALI20100128BHEP

Ipc: A61P 17/00 20060101ALI20100128BHEP

Ipc: A61K 31/55 20060101AFI20050629BHEP

Ipc: A61P 29/00 20060101ALI20100128BHEP

Ipc: A61P 1/00 20060101ALI20100128BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100505